Finally, and perhaps most importantly, prospective Phase IV post-marketing studies from pharmaceutical companies or governmental agencies that specifically focus on psychiatric AEs in non-NRT medications should be considered because they have much greater internal and external validity than the current AE reporting system. Inclusion of control groups of smokers trying to quit with NRT or without any medication would be helpful.
